Mirugen is a preclinical biotech spin-out from the Centre for Eye Research Australia that develops cell reprogramming technology to stimulate innate repair. Its core work targets retinal repair, advancing a lead Retinitis Pigmentosa programme that aims to regenerate photoreceptors by activating nascent Muller glial stem cells. The company intends to translate this approach to other causes of blindness, including Age‑related Macular Degeneration and Stargardt’s disease. Mirugen has complemented non-dilutive awards from CUREator with equity financing to support translational development. The company recently appointed Charlotte Casebourne Stock as Executive Chair to support progression toward the clinic. To date Mirugen has raised A$7.1 million, including a new A$4.5 million seed round. The proceeds will fund further development of the core technology and the lead retinal programme.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2025